The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2016

Filed:

Aug. 23, 2006
Applicants:

Wilhelm Amberg, Mannheim, DE;

Astrid Netz, Mannheim, DE;

Andreas Kling, Mannheim, DE;

Michael Ochse, Bad Durkheim, DE;

Udo Lange, Berlin, DE;

Charles W. Hutchins, Green Oaks, IL (US);

Francisco Javier Garcia-ladona, Kandel, DE;

Wolfgang Wernet, Neustadt, DE;

Alfred Hahn, Mannheim, DE;

Inventors:

Wilhelm Amberg, Mannheim, DE;

Astrid Netz, Mannheim, DE;

Andreas Kling, Mannheim, DE;

Michael Ochse, Bad Durkheim, DE;

Udo Lange, Berlin, DE;

Charles W. Hutchins, Green Oaks, IL (US);

Francisco Javier Garcia-Ladona, Kandel, DE;

Wolfgang Wernet, Neustadt, DE;

Alfred Hahn, Mannheim, DE;

Assignees:

Abbott Laboratories, Abbott Park, IL (US);

AbbVie Deutschland GmbH & Co. KG, Wiesbaden, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/75 (2006.01); C07D 213/84 (2006.01); C07D 213/85 (2006.01); C07D 215/38 (2006.01); C07D 217/22 (2006.01); C07D 239/42 (2006.01); C07D 409/04 (2006.01); A61K 31/44 (2006.01); A61K 31/47 (2006.01); A61K 31/505 (2006.01);
U.S. Cl.
CPC ...
C07D 213/75 (2013.01); A61K 31/44 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); C07D 213/84 (2013.01); C07D 213/85 (2013.01); C07D 215/38 (2013.01); C07D 217/22 (2013.01); C07D 239/42 (2013.01); C07D 409/04 (2013.01);
Abstract

The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders.


Find Patent Forward Citations

Loading…